Neuronetics Expands Access to Mental Health Treatment
MALVERN, Pa. — Neuronetics, Inc. (NASDAQ: STIM) has taken significant steps to make transcranial magnetic stimulation (TMS) therapy more accessible, especially for those dealing with major depressive disorder (MDD). The company, focused on innovative neurohealth treatments, announced that several insurance payors are now more open to covering TMS therapy. This enhancement is vital for patients who haven’t achieved relief with traditional medications.
New Insurance Policies for Teens and Adults
As part of this effort, BlueCross BlueShield (BCBS) of North Carolina has recently updated its TMS coverage to now include adolescents aged 15 and older. This change comes after the recent FDA approval of NeuroStar, which is recognized as the first and only TMS treatment specifically cleared for adolescents. These adjustments are expected to positively impact the mental health of over 2.2 million individuals covered by BCBS in North Carolina.
Louisiana Medicaid Joins the Effort
Furthermore, Louisiana Medicaid has begun covering TMS therapy for adults aged 18 and up. This marks a new era of TMS treatment options for adults in Louisiana, benefiting a state where this new policy will influence more than 1.6 million lives.
CEO Comments on Recent Policy Changes
Keith J. Sullivan, the President and CEO of Neuronetics, expressed excitement about these changes, saying, "We’re thrilled to see expanded health policies that widen access to NeuroStar TMS Therapy for those suffering from depression. This demonstrates a crucial progression, especially as payors acknowledge the urgent need for effective mental health treatment. Our aim is to support patients, particularly given the current shortage of mental health professionals."
A Wave of Change
These policy updates indicate a broader movement among both commercial and government payers aimed at lessening barriers to TMS therapy. Neuronetics has previously celebrated similar expansions with other payors, including Aetna and California Medicaid, showcasing their dedication to enhancing access to mental health care.
Pioneering Health Policy Advocacy
What distinguishes Neuronetics isn’t just its cutting-edge TMS technology but also its proactive strategy in health policy advocacy. The company has a dedicated team that works closely with healthcare providers and payors to push for essential updates to coverage. It’s noteworthy that Neuronetics is the only TMS company that has received FDA clearance for treating adolescents.
Understanding NeuroStar TMS Therapy
Neuronetics’ NeuroStar TMS Therapy provides a non-invasive, drug-free option for those facing neurohealth challenges, particularly individuals struggling with MDD. This therapy is designed for both adults and adolescents aged 15-21 who are experiencing episodes of depression. NeuroStar has established itself as a leader in the field, delivering over 6.6 million treatments and ensuring that patients receive the high-quality care they need.
Contact Us for More Information
If you’re interested in learning more about NeuroStar TMS Therapy and how it can assist those grappling with mental health issues, visit www.neurostar.com. The company is committed to enhancing patient lives through innovative solutions and expanding vital mental health care access.
Frequently Asked Questions
What is TMS therapy?
Transcranial Magnetic Stimulation (TMS) therapy is a non-invasive treatment that uses magnetic fields to stimulate nerve cells in the brain, helping to reduce symptoms of depression.
How does Neuronetics’ NeuroStar differ from other TMS therapies?
Neuronetics’ NeuroStar is the only TMS device that’s FDA-approved for use in adolescents and comes complete with a dedicated team advocating for health policy improvements to enhance access to treatments.
Who qualifies for TMS therapy?
Individuals suffering from major depressive disorder, particularly those who have not had success with standard medications, qualify for TMS therapy.
What is the significance of expanded insurance coverage?
Expanded coverage reduces barriers, enabling more patients to access essential mental health treatments earlier in their treatment journey.
What commitment does Neuronetics have to mental health?
Neuronetics is committed to provide innovative neurohealth solutions, ensuring that individuals facing mental health challenges have access to effective, non-invasive treatment options.
